More patients treated with dupilumab experienced sustained disease remission and itch reduction at week 36 compared with those who received placebo. The Food and Drug Administration (FDA) has approved ...

Please provide your email address to receive an email when new articles are posted on . Dupixent previously received priority review and orphan drug designation from the FDA for bullous pemphigoid.

Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with bullous pemphigoid treated with IL-2 had ...

DEAR DR. ROACH: I am a 73-year-old woman who is in otherwise good health, but I was diagnosed with bullous pemphigoid, a rare autoimmune disease, in January 2022. I have been treated by three ...

Anti-BP180 antibody levels demonstrated a moderate to strong correlation with the severity of bullous pemphigoid (BP), in a meta-analysis highlighting the potential of anti-BP180 as a tool to monitor ...

Study met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary ...